French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday.

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion — Positive
BPMC SNY WSJ — June 02, 2025The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

UMH Properties Preferred: A Discounted REIT Preferred With Long-Term Potential — Positive
UMH Seeking Alpha — June 02, 2025UMH Properties Series D preferred shares offer an attractive yield and trade at a discount, presenting a compelling long-term income opportunity. UMH has strong fundamentals, including high occupancy, positive income growth, and manageable leverage ratios. Potential risks include operational reliance on home sales, increased loan exposure, and vulnerability to economic downturns, but these are balanced by the REIT's track record.

Flex LNG - Finalize $175 million lease financing for Flex Courageous — Neutral
FLNG PRNewsWire — June 02, 2025HAMILTON, Bermuda , June 2, 2025 /PRNewswire/ -- Flex LNG Ltd. ("Flex LNG" or the "Company") (NYSE: FLNG) (OSE: FLNG) is pleased to announce the signing and successful completion of the $175 million JOLCO lease financing for the vessel Flex Courageous.

Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer — Neutral
NVS GlobeNewsWire — June 02, 2025Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, …

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology — Neutral
BPMC SNY GlobeNewsWire — June 02, 2025Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology — Neutral
BPMC SNY GlobeNewsWire — June 02, 2025Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology — Neutral
BPMC SNY GlobeNewsWire — June 02, 2025Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET — Neutral
WKEY GlobeNewsWire — June 02, 2025WISeKey to Present at Maxim Tech Conference “Discover the Innovations Reshaping Tomorrow” on June 3 at 8:30am ET

ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) -- Reference is made to the key information relating to Q1 2025 dividend announced by Okeanis Eco Tankers Corp. ("OET" or the "Company") (NYSE: ECO / OSE: OET) on May 14, 2025. The Company's shares will be traded ex dividend USD 0.32 per common share on the Oslo Stock Exchange from today, June 2, 2025 and on the New York Stock Exchange from June 3, 2025.

The Preferred Stock IPO Market 'Unfroze' In May — Positive
FOUR MFIN WTFC Seeking Alpha — June 01, 2025Summarized key new preferred stock and exchange traded debt offerings, highlighting dividend rates, conversion terms, and credit ratings for each issue. Explained how retail investors can access newly issued preferred shares at wholesale prices via OTC trading before permanent exchange listing. Discussed the challenges of non-standardized preferred stock trading symbols across brokers and provided resources for cross-referencing.

Top 10 High-Yield Dividend Stocks — Positive
CMCSA EOG MRK NEE PEP PNC QSR SPY STT VYM WTRG XEL Seeking Alpha — June 01, 2025The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superior dividend yield. The June 2025 watchlist includes 10 stocks with an average forward dividend yield of 3.62% and an expected return of 13.63%.

Sezzle: Giving The Affirmative On This Underappreciated BNPL Gem — Positive
SEZL Seeking Alpha — June 01, 2025Sezzle's Q1 2025 Gross Merchandise Volume rose 64.1% year-over-year to $808.7 million, driven by higher purchase frequency and growing monthly active users, highlighting increasing user satisfaction and platform stickiness. Total revenue jumped 123.3% year-over-year to $104.9 million, with a record-high 13% GMV conversion rate—far exceeding peers like Affirm and Klarna—while achieving a net income margin of 34.5%. Sezzle stands out in the BNPL space through features like Sezzle Up (credit reporting), subscription-based perks, built-in spending guardrails, and financial wellness tools—fostering both customer retention and responsible lending.

CoreWeave's early pivot to AI cloud and aggressive GPU acquisition created a supply moat, fueling hypergrowth and multi-year, take-or-pay contracts with top AI clients. Proprietary NVLink-connected clusters deliver superior performance and cost efficiency, enabling premium pricing and industry-leading margins as capacity utilization rises. Contracted backlog covers five years of revenue, supporting high visibility and justifying heavy capex and leverage, with manageable liquidity and project-finance-like debt.

Replacing Warren Buffett's Insurance Mastermind Is Berkshire's Next Succession Mystery — Neutral
BRK-A BRK-B WSJ — June 01, 2025Who should take over for Ajit Jain—the brains behind Berkshire Hathaway's insurance powerhouse—when he is ready to step down? Berkshire watchers have some ideas.

Citi names Bank of America veteran Zhang as new China country head — Neutral
C Reuters — June 01, 2025Citigroup said on Monday it had appointed Wenjie Zhang as its new country officer and banking head for China, after the exit of its former China head in November.

Palliser Capital Publishes Value Enhancement Plan for Toyo Tires — Neutral
TOYO Business Wire — June 01, 2025LONDON--(BUSINESS WIRE)--Palliser Capital (“Palliser”), a significant shareholder in Toyo Tires (“Toyo”) (5105 JT), today published a comprehensive presentation on the opportunities available to unlock value at Toyo. To ensure market transparency and respond to requests from shareholders and other stakeholders, Palliser published the presentation first delivered by James Smith, Palliser Founder and Chief Investment Officer, at the Sohn Hong Kong Investment Leaders Conference on May 30, 2025. To.

Rio Tinto Agrees to New Management Plan in Area Where It Destroyed Ancient Caves — Neutral
RIO WSJ — June 01, 2025Rio Tinto has agreed to a new management plan with a local indigenous group that covers its iron-ore operations in an area of Australia's Pilbara region where it destroyed two ancient rock shelters five years ago.
